Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Boehringer Ingelheim
Colorcon
McKesson
Dow

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR RETROVIR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Retrovir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000662 ↗ A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease Completed Glaxo Wellcome N/A 1969-12-31 To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.
NCT00000662 ↗ A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.
NCT00000716 ↗ A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age. The effectiveness of AZT in treating HIV infection in infants and children will also be evaluated. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in altering the course of the disease and decreasing mortality in these children. AZT has been shown to be effective in certain adult patients with symptomatic HIV infection. It is therefore likely that infected children may also benefit from this treatment.
NCT00002020 ↗ Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC Completed Glaxo Wellcome N/A 1969-12-31 To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.
NCT00002028 ↗ A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir) Completed Bristol-Myers Squibb N/A 1969-12-31 The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geographic location.
NCT00002044 ↗ A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases Completed Glaxo Wellcome N/A 1969-12-31 The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a lymphotropic and neurotropic virus which can affect both the central and peripheral nervous systems (CNS, PNS). There is evidence that the CNS and PNS may harbor the virus in a latent state, with the potential for continuous reinfection of other body systems. Therefore, effective therapeutic efforts against HIV infection should provide effective antiviral activity within the nervous system.
NCT00002045 ↗ A Prospective Double-Blind Study of Retrovir in Early HIV Infection Completed Glaxo Wellcome N/A 1969-12-31 To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Retrovir

Condition Name

Condition Name for Retrovir
Intervention Trials
HIV Infections 36
HIV 4
Healthy 2
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Retrovir
Intervention Trials
HIV Infections 38
Acquired Immunodeficiency Syndrome 19
Infections 12
Infection 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Retrovir

Trials by Country

Trials by Country for Retrovir
Location Trials
United States 139
South Africa 11
Puerto Rico 6
Brazil 6
Zimbabwe 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Retrovir
Location Trials
Texas 12
Florida 11
California 11
North Carolina 11
New York 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Retrovir

Clinical Trial Phase

Clinical Trial Phase for Retrovir
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Retrovir
Clinical Trial Phase Trials
Completed 45
Terminated 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Retrovir

Sponsor Name

Sponsor Name for Retrovir
Sponsor Trials
Glaxo Wellcome 15
National Institute of Allergy and Infectious Diseases (NIAID) 11
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 6
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Retrovir
Sponsor Trials
Industry 30
NIH 25
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Johnson and Johnson
Baxter
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.